Latest News

November 26, 2012

New Publication: Predictors of Peanut Sensitization to Identify Infants at High-Risk for Peanut Allergy

Oral Immunotherapy is known to be an effective means of desensitizing some patients to food allergens, but could the early introduction of foods in high-risk patients prevent allergies altogether?

> read more
November 15, 2012

In Memory of George Eisenbarth, MD

With deep regret and sadness we note the passing of George Eisenbarth, MD, a member of the ITN family, steering committee, and executive committee since the founding of the network.  George was a pioneer in the field of type 1 diabetes research, a great mentor to many, and a wonderful colleague, whose passion for preventing autoimmune diabetes energized us all. 

> read more
November 7, 2012

Data from ITN RAVE Study to be presented at American College of Rheumatology Meeting

Three abstracts from the ITN’s RAVE study (Rituximab for the Treatment of ANCA-associated Vasculitis  and Microscopic Polyangiitis) will be presented at the upcoming American College of Rheumatology (ACR) annual meeting in Washington, DC November on 9-14, 2012.John Stone, MD (Massachusetts General Hospital) will present “Primary Endpoint Failure in the Rituximab in ANCA-Associated Vasculitis Trial” (Miloslavsky et al.), which explores potential explanations for why certain patients were primary endpoint failures (November 12th, 3pm).

> read more
September 27, 2012

Type 1 Diabetes Data to be presented at European Association for the Study of Diabetes

Data from three Immune Tolerance Network (ITN) type 1 diabetes studies will be presented at the upcoming European Association for the Study of Diabetes (EASD) meeting on October 1-5, 2012 in Berlin, Germany.Mario Ehlers, MD, PhD (Immune Tolerance Network) will present preliminary data from the ITN’s RETAIN Study in an oral abstract: “Alpha-1 antitrypsin therapy in new-onset type 1 diabetes: interim results from Part I of the RETAIN study” (Thursday, October 4th, 10:45-11:00am).

> read more
September 21, 2012

New Publication: Grass Pollen Nasal Allergen Challenge for Assessing Outcomes

Immune Tolerance Network (ITN) investigators Stephen Durham, MD and Guy Scadding, MD from the Imperial College London conducted a pilot study in collaboration with ALK Abello to evaluate a technique to reproducibly measure time-dependent immunologic responses to allergens using nasal secretion collections.

> read more
August 23, 2012

New Publication: IL-2 and Rapamycin in Type 1 Diabetes

Results from the IL2-RAPA ITN018AI study, exploring a novel experimental therapy for type 1 diabetes that boosts parts of the healthy immune system, are reported today in the scientific journal Diabetes.

> read more
August 16, 2012

A View Towards (Immune) Tolerance – Part 5

Detailed below is the fifth and final achievement the Immune Tolerance Network (ITN) recently presented at the Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting, and how this work fits in with the broader pursuit of tolerance in transplantation.

> read more
August 13, 2012

A View Towards (Immune) Tolerance – Part 4

Detailed below is a fourth achievement the Immune Tolerance Network (ITN) recently presented at the Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting, and how this work fits in with the broader pursuit of tolerance in allergy.

> read more
August 9, 2012

A View Towards (Immune) Tolerance – Part 3

Detailed below is a third achievement the Immune Tolerance Network (ITN) recently presented at the Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting, and how this work fits in with the broader pursuit of tolerance in transplantation.

> read more
August 6, 2012

A View Towards (Immune) Tolerance – Part 2

Detailed below is a second achievement the Immune Tolerance Network (ITN) recently presented at the Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting, and how this work fits in with the broader pursuit of tolerance in autoimmunity.

> read more